Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.29, read 2026-11-05
Ethical passes the values gate
Price902.90 USD
Fair value1,030.00
Ethical score69.9/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-11-06Read Markup902.90+0.0% to today ✓Accumulation gives way to Markup after a 13% rise in 9 days
2026-10-28Read Accumulation796.34+13.4% to today ✓Markup gives way to Accumulation first Accumulation read since August
2026-10-18Read Markup796.34+13.4% to today ✓Markdown gives way to Markup first Markup read since July
2026-10-11Read Markdown788.04+14.6% to today Distribution gives way to Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Regeneron Pharmaceuticals holds its Markup at $902.90. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$902.90
Valuation
20.25 trailing · 13.03 forward price to earnings
Values screen
PASS· score 69.9
Beta
0.15
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
6.67%
Below 33%
Interest-bearing debt is just 6.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
25.30%
Below 33%
Cash held in interest-bearing accounts and securities is 25.3% of assets, under the one-third limit.
Pass
Receivables
21.84%
Below 49%
Money owed to the company is 21.8% of assets, under the 49% limit.
Pass
Revenue purity
5.00%
Below 5%
Only 5.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Regeneron Pharmaceuticals clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 7%, inside the ~33% line, and interest is about 5% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when REGN's ethical verdict changes
Today REGN passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 12% discount to our $1,030.00 fair value, moderate competitive moat, 16.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 12.3% discount to the base estimate.
Where our models see it going: fair-value estimate $1,030.00, with a range of $1,030.00 to $1,727.53, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech Pipeline Delivers Steady Cash and Growth
A medicine that actually clears blocked vision or calms severe inflammation can shift from lab bench to patient in a few years and start paying back fast. Regeneron keeps turning that process into reliable revenue.
The company grows sales 19 percent a year, holds a 30 percent profit margin and trades at 12.4 times forward earnings. A moderate moat, clean ethical screen and 48 percent gap to our fair value mark it as an opportunity rather than a story stock.
Pipeline setbacks and fresh competition remain real threats in biotech, while 15 percent return on equity shows capital still works harder elsewhere. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
REGN trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-06Markup · changed$902.90+10.3%Entry 23
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $978.
2026-10-30Accumulation$818.77+0.7%Entry 22
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $869. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$813.27+2.1%Entry 21
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $867. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $867. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$796.34+0.0%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $867. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$796.34+0.0%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $867. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$796.34+0.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $867. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markup$796.34+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $867. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markup$796.34+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $865. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup · changed$796.34+1.1%Entry 14
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $864.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
